Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Current Assets (2016 - 2026)

Avanos Medical's Current Assets history spans 13 years, with the latest figure at $355.4 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 9.66% to $355.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $355.4 million, a 9.66% decrease, with the full-year FY2025 number at $355.4 million, down 9.66% from a year prior.
  • Current Assets hit $355.4 million in Q4 2025 for Avanos Medical, up from $351.4 million in the prior quarter.
  • Over the last five years, Current Assets for AVNS hit a ceiling of $624.1 million in Q4 2022 and a floor of $351.4 million in Q3 2025.
  • Historically, Current Assets has averaged $444.5 million across 5 years, with a median of $445.7 million in 2021.
  • Biggest five-year swings in Current Assets: dropped 28.65% in 2021 and later soared 45.95% in 2022.
  • Tracing AVNS's Current Assets over 5 years: stood at $427.6 million in 2021, then soared by 45.95% to $624.1 million in 2022, then decreased by 21.97% to $487.0 million in 2023, then decreased by 19.22% to $393.4 million in 2024, then decreased by 9.66% to $355.4 million in 2025.
  • Business Quant data shows Current Assets for AVNS at $355.4 million in Q4 2025, $351.4 million in Q3 2025, and $356.0 million in Q2 2025.